Log in
H2 receptor antagonist

Famotidine

Famotidine is a histamine H2 receptor antagonist that suppresses gastric acid secretion by blocking histamine binding to H2 receptors on parietal cells. It is widely used for peptic ulcer disease, gastroesophageal reflux disease (GERD), and prevention of stress ulcers. The most testable fact is that famotidine is safer in renal impairment and drug interactions than proton pump inhibitors, but less potent in acid suppression.

Practice questionsHigh-yield facts
Drug classHistamine H2 receptor antagonist
MechanismCompetitive blockade of H2 receptors on gastric parietal cells
Main usesGERD, peptic ulcer disease, stress ulcer prophylaxis
Key adverse effectHeadache, dizziness; rare thrombocytopenia and confusion in elderly
5 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Famotidine is a competitive antagonist at histamine H2 receptors located on the basolateral membrane of gastric parietal cells. By blocking histamine binding, famotidine inhibits both basal and stimulated gastric acid secretion.

Histamine, acetylcholine, and gastrin all stimulate parietal cells to secrete hydrochloric acid. Histamine acts via H2 receptors coupled to adenylyl cyclase, increasing intracellular cAMP and activating protein kinase A, which ultimately activates the H⁺/K⁺-ATPase proton pump. Famotidine blocks the histamine pathway but does not directly inhibit the proton pump itself, which distinguishes it from proton pump inhibitors (PPIs).

Famotidine reduces gastric acid output by approximately 60–70% over 24 hours at standard doses. It suppresses nocturnal acid secretion effectively, making it useful for conditions where nighttime acid breakthrough occurs. Unlike PPIs, H2 receptor antagonists do not require acid activation and work immediately upon administration, though their maximal acid suppression is less profound than PPIs.

High-yield for exams
  • Famotidine competitively blocks H2 receptors on parietal cells, reducing gastric acid secretion by ~60–70%.
  • Tolerance (tachyphylaxis) develops in 2–4 weeks with continuous use, limiting long-term efficacy.
  • Famotidine is renally cleared; dose reduction required when CrCl <50 mL/min to prevent CNS toxicity.
  • Safe alternative to PPIs in patients on clopidogrel—does not inhibit CYP2C19 or reduce antiplatelet effect.
  • Confusion and delirium may occur in elderly patients or those with renal impairment due to drug accumulation.
  • Less potent than PPIs but faster onset and fewer long-term risks (no increased fracture or C. difficile risk).
  • Raises gastric pH and reduces absorption of ketoconazole, itraconazole, atazanavir, and iron salts.
  • Rare adverse effects include thrombocytopenia, QT prolongation, and hypersensitivity reactions.

Indications

Famotidine is FDA-approved for:

  • Gastroesophageal reflux disease (GERD): symptomatic relief of heartburn and esophagitis
  • Peptic ulcer disease: treatment and maintenance therapy for duodenal and gastric ulcers
  • Pathological hypersecretory conditions: Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas
  • Stress ulcer prophylaxis: in critically ill patients to prevent stress-related mucosal damage

Off-label uses include:

  • Dyspepsia and functional heartburn
  • Prevention of NSAID-induced ulcers (though PPIs are preferred)
  • Aspiration prophylaxis before anesthesia in high-risk patients

Famotidine is available over-the-counter for relief of heartburn and acid indigestion. It has largely been supplanted by PPIs for severe acid-related disorders but remains a safe alternative when PPIs are contraindicated or cause intolerable side effects.

Pharmacokinetics

Absorption: Famotidine is absorbed incompletely (40–45% bioavailability) after oral administration. Peak plasma concentrations occur 1–3 hours after dosing. Food may delay absorption slightly but does not significantly reduce bioavailability.

Distribution: Protein binding is low (15–20%). Famotidine distributes into gastric mucosa and achieves therapeutic concentrations at the site of action.

Metabolism: Famotidine undergoes minimal hepatic metabolism. Approximately 65–70% of an oral dose is excreted unchanged in the urine.

Elimination: The elimination half-life is 2.5–3.5 hours in patients with normal renal function. Renal clearance is the primary route of elimination, and dosage adjustment is required in renal impairment (CrCl <50 mL/min). In patients with severe renal dysfunction, the half-life may be prolonged to 20 hours or more.

Onset and duration: Acid suppression begins within 1 hour of oral dosing and persists for 10–12 hours. Intravenous administration produces more rapid onset.

Adverse effects

Famotidine is generally well tolerated, with a favorable safety profile compared to many other medications.

Common adverse effects

  • Headache (most common)
  • Dizziness
  • Constipation or diarrhea
  • Fatigue

Serious adverse effects

  • Thrombocytopenia: rare but reversible upon discontinuation
  • CNS effects in elderly or renally impaired patients: confusion, agitation, hallucinations, seizures (more common with high doses or accumulation)
  • Cardiac arrhythmias: QT prolongation (rare, mostly with IV administration)
  • Hepatotoxicity: rare elevations in liver enzymes
  • Hypersensitivity reactions: rash, bronchospasm, anaphylaxis (very rare)

Long-term considerations

Unlike PPIs, famotidine does not significantly increase the risk of Clostridioides difficile infection, community-acquired pneumonia, or osteoporosis-related fractures. Tolerance (tachyphylaxis) can develop with continuous use over 2–4 weeks, reducing efficacy—this is a key reason PPIs are preferred for chronic acid suppression.

Contraindications and warnings

Contraindications:

  • Hypersensitivity to famotidine or other H2 receptor antagonists

Warnings and precautions:

  • Renal impairment: Dose reduction is necessary when CrCl <50 mL/min to prevent drug accumulation and CNS toxicity.
  • Elderly patients: Increased risk of confusion and delirium, especially with renal dysfunction.
  • Gastric malignancy: Symptomatic response to famotidine does not rule out gastric cancer. Investigate alarm symptoms (weight loss, dysphagia, bleeding) before initiating therapy.
  • QT prolongation: Use caution in patients with risk factors for arrhythmias or those receiving other QT-prolonging drugs.
  • Pregnancy: Category B. Famotidine crosses the placenta but has not been associated with fetal harm in human studies. It is considered safer than PPIs during pregnancy in many guidelines.
  • Breastfeeding: Famotidine is excreted in breast milk in small amounts; use with caution.

Drug-specific warnings: Abrupt withdrawal after long-term use may cause rebound acid hypersecretion, though this is less pronounced than with PPIs.

Drug interactions

Famotidine has a low potential for drug interactions compared to PPIs, as it does not inhibit cytochrome P450 enzymes.

Absorption interactions

  • Ketoconazole, itraconazole, atazanavir: Famotidine raises gastric pH, reducing absorption of drugs that require acidic conditions. Separate administration or use alternative antifungals/antiretrovirals.
  • Iron salts: Reduced absorption of oral iron supplements due to decreased gastric acidity.

Miscellaneous interactions

  • Antacids: May reduce famotidine absorption if given simultaneously. Separate by 1–2 hours.
  • Warfarin: Rare reports of altered INR; monitor if coadministered, though interaction is uncommon.
  • Bone marrow suppressants: Theoretical additive risk of thrombocytopenia with other myelosuppressive agents.

Famotidine does not significantly interact with clopidogrel, a key advantage over PPIs (which inhibit CYP2C19 and reduce clopidogrel activation).

Clinical pearls

  • H2 receptor antagonists vs. PPIs: Famotidine is less potent than PPIs for acid suppression but acts faster and has fewer long-term safety concerns. It is preferred for mild GERD, nocturnal acid breakthrough on PPIs, or when PPIs are contraindicated.
  • Tachyphylaxis: Tolerance to H2 blockers develops in 2–4 weeks with continuous use, limiting their effectiveness for chronic therapy. This does not occur with PPIs.
  • Renal dosing is critical: Famotidine accumulates in renal failure. Dose reduction or interval extension is required when CrCl is below 50 mL/min.
  • CNS side effects in elderly: Watch for confusion or delirium in older patients, especially with impaired renal function.
  • Safe with clopidogrel: Unlike omeprazole and esomeprazole, famotidine does not reduce clopidogrel efficacy—use it in patients on dual antiplatelet therapy who need acid suppression.
  • Stress ulcer prophylaxis: Famotidine is commonly used in ICU patients, though PPIs are increasingly preferred. Both reduce bleeding risk but may increase pneumonia and C. difficile infection.
  • Zollinger-Ellison syndrome: Famotidine can be used but requires much higher doses than standard therapy; PPIs are now first-line.
  • Over-the-counter use: Widely available for self-treatment of heartburn. Counsel patients to seek medical evaluation if symptoms persist beyond 2 weeks.
Mnemonic

FAMOTIDINE for H2 blocker features: Faster onset than PPIs, Acid reduced ~60%, Metabolism minimal (renal excretion), Older patients → confusion risk, Tolerance develops (tachyphylaxis), Interactions few (safe with clopidogrel), Dose adjust in renal disease, Inferior potency vs. PPIs, No CYP450 inhibition, Elderly/renal → CNS effects.

Practice questions

1. A 68-year-old man with chronic kidney disease (CrCl 25 mL/min) is admitted to the ICU for sepsis. He is started on stress ulcer prophylaxis with famotidine at the standard dose. On day 3, he becomes confused and agitated. Vital signs are stable, and metabolic panel shows no acute changes. What is the most likely cause of his altered mental status?

Answer: C. Famotidine is renally cleared, and this patient's CrCl of 25 mL/min places him at high risk for drug accumulation if the dose is not adjusted. CNS toxicity, including confusion, agitation, and delirium, is a well-known complication of famotidine overdose, particularly in elderly patients with renal dysfunction. The standard dose should have been reduced in this patient. Septic encephalopathy is possible but less likely given stable vitals and no metabolic derangements.

2. A 55-year-old woman with a history of acute coronary syndrome is on aspirin and clopidogrel. She develops symptomatic GERD and asks for acid suppression therapy. Her physician is concerned about drug interactions with clopidogrel. Which medication is the most appropriate choice?

Answer: D. Famotidine is the best choice because it does not inhibit CYP2C19, the enzyme responsible for converting clopidogrel to its active form. Omeprazole and esomeprazole are strong CYP2C19 inhibitors and significantly reduce clopidogrel efficacy, increasing the risk of cardiovascular events. Pantoprazole has less interaction but is not entirely free of risk. Famotidine, as an H2 receptor antagonist, avoids this interaction entirely and is recommended in patients on dual antiplatelet therapy.

3. A 40-year-old man with Zollinger-Ellison syndrome is being treated with famotidine. Despite high-dose therapy, his symptoms of abdominal pain and diarrhea persist, and gastric pH monitoring shows inadequate acid suppression. What is the most appropriate next step in management?

Answer: B. Proton pump inhibitors (e.g., omeprazole, pantoprazole) are first-line therapy for Zollinger-Ellison syndrome because they provide more profound and sustained acid suppression than H2 receptor antagonists. Famotidine can be used at very high doses, but PPIs are far more effective and are now the standard of care. Sucralfate provides mucosal protection but does not reduce acid secretion. Octreotide is used adjunctively in refractory cases or metastatic disease but is not first-line. Vagotomy is outdated.

Frequently asked questions

How does famotidine work?

Famotidine works by competitively blocking histamine H2 receptors on gastric parietal cells, which prevents histamine from stimulating acid secretion. This reduces both basal and meal-stimulated gastric acid production by approximately 60–70%. Unlike proton pump inhibitors, famotidine does not directly inhibit the H⁺/K⁺-ATPase pump but blocks one of the three pathways (histamine, acetylcholine, gastrin) that activate it. The effect begins within 1 hour and lasts 10–12 hours.

What are the side effects of famotidine?

Famotidine is generally well tolerated. The most common side effects are headache, dizziness, constipation, and diarrhea. Serious but rare adverse effects include thrombocytopenia (low platelet count), confusion or delirium (especially in elderly or renally impaired patients), and QT prolongation. Unlike proton pump inhibitors, famotidine does not significantly increase the risk of bone fractures, Clostridioides difficile infection, or pneumonia with long-term use. Tolerance may develop after 2–4 weeks of continuous therapy.

Is famotidine safer than omeprazole?

Famotidine and omeprazole have different safety profiles. Famotidine is safer for patients on clopidogrel because it does not inhibit CYP2C19 and does not reduce antiplatelet efficacy, whereas omeprazole does. Famotidine also has fewer long-term risks such as osteoporosis-related fractures and Clostridioides difficile infection. However, omeprazole is more potent for acid suppression and preferred for severe GERD or peptic ulcer disease. Famotidine requires renal dose adjustment and can cause confusion in the elderly, which is less common with omeprazole.

Can you take famotidine long-term?

Famotidine can be taken long-term, but tolerance (tachyphylaxis) often develops after 2–4 weeks of continuous use, reducing its effectiveness. For this reason, proton pump inhibitors are usually preferred for chronic acid suppression. Long-term famotidine is generally safe and does not carry the same risks as PPIs (bone fractures, vitamin B12 deficiency, chronic kidney disease). However, in patients with renal impairment, dose adjustment is essential to prevent drug accumulation and CNS side effects such as confusion.

Does famotidine need to be dose-adjusted in kidney disease?

Yes, famotidine requires dose adjustment in renal impairment because it is primarily eliminated by the kidneys. When creatinine clearance falls below 50 mL/min, the dose should be reduced or the dosing interval extended to prevent drug accumulation. Failure to adjust the dose can lead to CNS toxicity, including confusion, agitation, and seizures, especially in elderly patients. Always assess renal function before prescribing famotidine.

Conditions it is used for

Gastroesophageal reflux disease (GERD)Peptic ulcer diseaseDuodenal ulcerGastric ulcerZollinger-Ellison syndromeHeartburnDyspepsiaStress ulcer
ranitidinecimetidinenizatidineomeprazoleesomeprazolepantoprazolelansoprazolerabeprazole

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A02BA03

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.